Page last updated: 2024-10-25

cilostazol and Diabetic Angiopathies

cilostazol has been researched along with Diabetic Angiopathies in 16 studies

Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Research Excerpts

ExcerptRelevanceReference
"This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy."9.17Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."9.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
" Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication."9.09Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. ( Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS, 2001)
"Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade."6.73A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008)
"This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy."5.17Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."5.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
" Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication."5.09Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. ( Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS, 2001)
"Patients on cilostazol were divided into 4 groups according to arterial occlusive disease etiology: (1) atherosclerosis, (2) diabetic angiopathy, (3) embolism/thrombosis, and (4) Buerger disease."4.31Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol? ( Arslan, K; Can Depboylu, B; Funda Tetik, M; Harmandar, B; Ilhan, G; Istar, H; Yazman, S, 2023)
"Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade."2.73A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008)
" The measurement of digital skin temperatures by infrared thermography provided a noninvasive means to individualize the dosage of cilostazol and to monitor the cilostazol effect and patient complicance during long-term administration."2.67Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. ( Furukawa, H; Murakami, T; Uchikawa, T, 1992)
"Cilostazol has potential for protecting vessels against hyperglycemic injury and for accelerating the healing process after implantation of DES."1.39Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model. ( Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS, 2013)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's8 (50.00)29.6817
2010's6 (37.50)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Can Depboylu, B1
Yazman, S1
Harmandar, B1
Funda Tetik, M1
Istar, H1
Arslan, K1
Ilhan, G1
Su, SC1
Hung, YJ1
Huang, CL1
Shieh, YS1
Chien, CY1
Chiang, CF1
Liu, JS1
Lu, CH1
Hsieh, CH1
Lin, CM1
Lee, CH1
Kwon, JS1
Kim, YS3
Cho, HH1
Kee, HJ1
Hong, MH1
Kang, WS1
Jeong, HY1
Jeong, MH1
Ahn, Y1
Asal, NJ1
Wojciak, KA1
Angiolillo, DJ2
Capranzano, P2
Goto, S1
Aslam, M1
Desai, B2
Charlton, RK1
Suzuki, Y1
Box, LC1
Shoemaker, SB1
Zenni, MM1
Guzman, LA1
Bass, TA1
Rhee, SY1
Chon, S1
Oh, S1
Woo, JT1
Kim, SW1
Kim, JW1
Fu, Q1
Yokoyama, N1
Takada, K1
Ishikawa, S1
Isshiki, T1
Ferreiro, JL1
Ueno, M1
Capodanno, D1
Dharmashankar, K1
Darlington, A1
Tello-Montoliu, A1
Rollini, F1
Hittel, N1
Donnelly, R1
Lee, SW1
Park, SW2
Kim, YH1
Yun, SC1
Park, DW1
Lee, CW1
Hong, MK1
Kim, HS1
Ko, JK1
Park, JH1
Lee, JH1
Choi, SW1
Seong, IW1
Cho, YH1
Lee, NH1
Kim, JH1
Chun, KJ1
Park, SJ1
Lipsitz, EC1
Kim, S1
Falconer, TM1
Eikelboom, JW1
Hankey, GJ1
Norman, PE1
Ahn, CW1
Lee, HC1
Song, YD1
Huh, KB1
Oh, SJ1
Choi, YK1
Kim, JM1
Lee, TH1
Lee, TM1
Su, SF1
Tsai, CH1
Lee, YT1
Wang, SS1
Shinoda-Tagawa, T1
Yamasaki, Y1
Yoshida, S1
Kajimoto, Y1
Tsujino, T1
Hakui, N1
Matsumoto, M1
Hori, M1
Uchikawa, T1
Murakami, T1
Furukawa, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]Phase 480 participants (Actual)Interventional2009-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for cilostazol and Diabetic Angiopathies

ArticleYear
Effect of cilostazol in treating diabetes-associated microvascular complications.
    Endocrine, 2017, Volume: 56, Issue:2

    Topics: Cilostazol; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; Tetrazoles

2017
Treating peripheral arterial disease in patients with diabetes.
    Diabetes, obesity & metabolism, 2002, Volume: 4 Suppl 2

    Topics: Cilostazol; Diabetic Angiopathies; Disease Progression; Humans; Peripheral Vascular Diseases; Phosph

2002
Management of peripheral arterial disease in the elderly: focus on cilostazol.
    Clinical interventions in aging, 2008, Volume: 3, Issue:1

    Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy

2008

Trials

7 trials available for cilostazol and Diabetic Angiopathies

ArticleYear
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
    European heart journal, 2008, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove

2008
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Jan-01, Volume: 81, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies

2013
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
    Journal of the American College of Cardiology, 2008, Mar-25, Volume: 51, Issue:12

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest

2008
Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2001, Volume: 52, Issue:1

    Topics: Blood Glucose; Blood Pressure; Carotid Artery, Common; Cilostazol; Coronary Disease; Diabetes Mellit

2001
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Clinical science (London, England : 1979), 2001, Volume: 101, Issue:3

    Topics: Aged; Cilostazol; Diabetic Angiopathies; Double-Blind Method; Endothelial Growth Factors; Exercise T

2001
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.
    Diabetologia, 2002, Volume: 45, Issue:2

    Topics: Aged; Asian People; Carotid Arteries; Cerebral Infarction; Cilostazol; Diabetes Mellitus, Type 2; Di

2002
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
    Arzneimittel-Forschung, 1992, Volume: 42, Issue:3

    Topics: Adult; Aged; Arteriosclerosis Obliterans; Cilostazol; Diabetic Angiopathies; Female; Fingers; Humans

1992

Other Studies

6 other studies available for cilostazol and Diabetic Angiopathies

ArticleYear
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
    Texas Heart Institute journal, 2023, 01-01, Volume: 50, Issue:1

    Topics: Atherosclerosis; Cilostazol; Diabetic Angiopathies; Humans; Peripheral Arterial Disease; Quality of

2023
Cilostazol inhibits hyperglucose-induced vascular smooth muscle cell dysfunction by modulating the RAGE/ERK/NF-κB signaling pathways.
    Journal of biomedical science, 2019, Sep-06, Volume: 26, Issue:1

    Topics: Animals; Cilostazol; Diabetic Angiopathies; Glucose; Male; MAP Kinase Signaling System; Mice; Mice,

2019
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
    Atherosclerosis, 2013, Volume: 228, Issue:2

    Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucos

2013
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2011, Volume: 91, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty

2011
Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
    International heart journal, 2010, Volume: 51, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Cilostazol; Clopidogr

2010
Antithrombotic therapy in peripheral arterial disease.
    Cardiology clinics, 2008, Volume: 26, Issue:2

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie

2008